viernes, 6 de noviembre de 2026
BuscarExplore
es.VIA.NEWS
Via News Knowledge File

Johnson & Johnson Services, Inc.

organization80% conf.·synced Nov 6, 2026

Uses biomarkers to advance drug development and personalized treatment approaches across oncology, immunology, and neuroscience

60
sourced metrics
1273
relationships
20
stated objectives
0
Via News reports

Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →

Key metrics · each point sourced

Price 52 Week High
278.43USD
Nov 5, 2026reference only
Market Cap
656263585935USD
Nov 5, 2026reference only
Price 52 Week Low
186.57USD
Nov 5, 2026reference only
Stock Return Ytd
31.3%
Nov 5, 2026reference only
Stock Price
272.32USD
Nov 5, 2026reference only
Shares Outstanding
2409898597.0shares
Jul 17, 2026reference only
Revenue
25310000000.0USD
Jun 28, 2026reference only
Stockholders Equity
84971000000.0USD
Jun 28, 2026reference only
Cost Of Revenue
8051000000.0USD
Jun 28, 2026reference only
Total Assets
201061000000.0USD
Jun 28, 2026reference only
Gross Profit
17259000000.0USD
Jun 28, 2026reference only
Total Liabilities
116090000000.0USD
Jun 28, 2026reference only
Cash
20422000000.0USD
Jun 28, 2026reference only
Eps
2.27USD_per_share
Jun 28, 2026reference only
Net Income
5534000000.0USD
Jun 28, 2026reference only
Operating Cash Flow
2514000000.0USD
Mar 29, 2026reference only
Capex
1049000000.0USD
Mar 29, 2026reference only
Rd Expense
109000000.0USD
Dec 28, 2025reference only

Stated objectives

Achieve full-year 2025 sales of $93.5B-$93.9B, representing growth of 5.4%-5.9%

source
target: 93.5-93.9 billion USD stated

Improve adjusted pretax operating margin by approximately 300 basis points driven by cost savings and reduced acquired IPR&D costs

source
target: ~300 bps improvement stated

Achieve 2026 top-line growth of more than 5%, exceeding consensus of ~4.6%

source
target: >5% revenue growth stated

Achieve 2026 adjusted EPS approximately $0.05 above consensus of $11.39, implying ~$11.44

source
target: ~$11.44 adjusted EPS stated

Submit OTTAVA robotic surgical system for regulatory approval in the United States

source
target: Regulatory submission completed stated

Achieve higher operational sales growth in both Innovative Medicine and MedTech segments in 2026

source
by 2026-01-01 00:00:00stated

Improve MedTech growth and margins by completing the pending separation of the Orthopaedics franchise

source
stated

Strengthen presence in the neurological and psychiatric drug market via acquisition of Intra-Cellular Therapies

source
stated

Develop and deploy Ottava next-generation robotic surgery platform with AI-enabled ecosystem

source
stated

J&J expects sales growth in both Innovative Medicine and MedTech segments to be higher in 2026

source
target: higher than 2025 growth rates by 2026-01-01 00:00:00stated

Relationship graph · 1273 connections

Developed by
519
Competes with
133
subsidiary of
81
Covered by
73
Employs
69
Owns
59
acquired by
52
regulates
36
board member of
Joaquin Duato
This Knowledge File is assembled from Via News's source-traceable knowledge graph. Metrics, objectives and relationships are extracted from primary and credible secondary documents and refreshed on a schedule. Read our methodology →
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,996
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,996 hechos verificados con la fuente5,552 documentos fuente archivados
Consulta estos datos → isubstrate.com